

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**


As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>G01N 21/27</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/30742</b> <b>(43) International Publication Date:</b> 3 October 1996 (03.10.96)
<b>(21) International Application Number:</b> PCT/IB96/00260 <b>(22) International Filing Date:</b> 28 March 1996 (28.03.96) <b>(30) Priority Data:</b> 08/413,563 30 March 1995 (30.03.95) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/413,563 (CON) Filed on 30 March 1995 (30.03.95) <b>(71) Applicant (for all designated States except US):</b> CIBA CORNING DIAGNOSTICS CORP. [US/US]; 63 North Street, Medfield, MA 02052 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SCHARLACK, Ronald, S. [US/US]; 121 Colborne Crescent, Brookline, MA 02146 (US). <b>(74) Agent:</b> ROESLER, Judith, A.; 63 North Street, Medfield, MA 02052 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** METHOD FOR OXIMETER STANDARDIZATION AND FOR REPORTING RESULTS
$$\frac{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}$$
$$\frac{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}$$
$$\frac{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}{(bwd_1)_{\theta_{\text{ref}}}^{\text{ref}}}$$
**(57) Abstract**

The present invention comprises methods of determining the performance of an absorbance spectrometer, and, in particular, of CO-oximeters. The methods comprise measuring the absorbance spectrum of a quality control sample and comparing it to a standard spectrum of that quality control. Instrumental error will be the primary factor contributing to the observed difference. The present method also provides techniques for converting the instrumental error manifested in the difference between the measured and standard quality control spectra into blood concentration values comparable to that of real blood. Analysis of test samples on a spectrophotometer, and calibration of the spectrophotometer is also provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

## METHOD FOR OXIMETER STANDARDIZATION AND FOR REPORTING RESULTS

### Field of the Invention

This invention relates to the field assessing the performance of spectrophotometers.

### Summary of the Related Art

Ultraviolet-visible-infrared (UV-VIS-IR) absorbance spectroscopy has become an invaluable tool in medical diagnostics and analytical chemistry. For example, CO-oximeters measure the concentrations of various hemoglobin components or fractions in physiological blood using absorption spectroscopy. CO-oximeters perform this function by measuring the VIS-IR absorbance spectrum of a blood sample and determining the best fit of known blood component spectra.

It is easily appreciated, therefore, that it is important to be able to quickly and accurately determine instrument performance. Existing methods measure the absorbance spectrum of quality control products. QC products specific for blood analysis are typically red dye based samples constructed to simulate the spectrum of blood. In addition to a red dye, they sometimes contain certain amounts of oxygen, carbon dioxide, and electrolytes at an established pH for determining the performance of blood gas and electrolyte instruments. It is very difficult to construct QC products having an absorbance spectrum that closely mimics that of physiological blood.

Standard blood component spectra are used to obtain the best fit to the measured QC product spectrum. By varying the contributions of each blood component spectrum, a best fit to the QC spectrum is obtained. But because even the ideal QC spectrum does not mimic that of physiological blood well, the resulting best fit deviates from the observed QC spectrum even when the instrument is running

perfectly. Furthermore, instrument introduced errors are not reported in terms easily understood by the ordinary technician operating the instrument. For example, current methods report the fraction of the major blood components (as determined from the relative contribution of each blood component's spectrum to the best fit spectrum).  
5 Quite often a fractional concentration of a blood component is negative. Consequently, improved methods of determining and reporting instrument performance are desired.

### SUMMARY OF THE INVENTION

10 The present invention provides methods of determining and reporting the performance of VIS-IR spectrophotometers used to measure the concentration of hemoglobin components or fractions in blood samples. In particular, the method is used to determine the performance of CO-oximeters. In one aspect of the invention, the methods comprise measuring the absorbance spectrum of a quality control product  
15 (QC product) sample and comparing it to the known, standard spectrum for the same QC product. The known standard spectrum of the QC product is obtained from a well calibrated, highly precise spectrophotometer under controlled conditions and electronically stored in the instrument by the manufacturer for future comparison. The QC sample spectrum measured in commercial analytical instruments will differ  
20 from the standard spectrum primarily do to various instrumental errors. The standard spectrum is mathematically fit to the measured spectrum, yielding an apparent concentration of the QC. The difference between the measured spectrum and the best fit standard spectrum (the "error spectrum") and the variance of the apparent QC concentration from the standard QC concentration is a measure of the instrumental  
25 error.

One important use of the foregoing method is to gauge the performance of spectrophotometers used for analytical determinations including the concentration of various blood components. This method of determining instrumental performance is

5 easily conducted by the technician at the laboratory site and involves simply measuring the absorbance spectrum of a QC sample. The instrument can be programmed to automatically carry-out the foregoing procedure and report the instrumental error. If the observed instrumental error is too large, the instrument may need to be serviced before analysis of test samples.

This method is distinguishable from prior art methods because the measured spectrum closely resembles the standard spectrum to which it is compared. Furthermore, this method also allows the results to be reported in terms readily recognized and easily appreciated by the technician.

10 In another aspect of the present invention, the concentration of the QC obtained from the mathematical fit is converted into a total apparent hemoglobin concentration ( $T_{app}$ ). This is accomplished by multiplying the apparent concentration of the QC by a nominal value of the total hemoglobin concentration ( $T_{nom}$ ), which, in one aspect of the invention, is equal to the normal level of hemoglobin found in  
15 human blood.  $T_{app}$  is the total hemoglobin concentration one would have determined from the absorption spectrum of a test sample having a hemoglobin concentration of  $T_{nom}$ . This number is easily appreciated by the technician, and, if it differs too much from the nominal concentration of human hemoglobin, will indicate to the technician that the instrument may need servicing.

20 In another aspect, the QC spectrum and spectral measurement errors are conveniently translated into concentrations of blood components, i.e. hemoglobin fractions and lipid. This allows for ready recognition and appreciation of the QC results by technicians. This may be accomplished in one of two ways. The simplest way is to multiply the total apparent hemoglobin concentrations ( $T_{app}$ ) by a nominal  
25 fraction of each component in blood. The nominal fractions are preferably the fraction of the total hemoglobin concentration of the particular component (e.g., oxygenated hemoglobin) normally found in physiological blood. This method presents the same information contained in  $T_{app}$ , but in a different format.

The second, more preferred method of determining and reporting fractional blood component concentrations uses a mathematical analysis to determine the errors in concentrations of the major blood components due to instrumental errors. This method determines the values of the blood component concentrations that would give rise to the error spectrum. Several blood component spectra are mathematically combined to give the best fit to the error spectrum. The contributions of each blood component spectrum directly yield the concentration of the blood component. These concentrations are the deviations (owing to instrumental error) from the actual concentrations of these components that one would observe if an actual blood sample were analyzed. Adding these concentrations to the nominal concentrations of the blood components yields the concentrations of the blood components that would have been observed if a blood sample having the nominal concentrations of blood components were analyzed on the instrument. In a preferred embodiment, the nominal values of blood component concentrations are set to those values observed in normal human blood. The significance of the results then can be readily appreciated by the ordinary technician. If the errors are beyond acceptable limits, servicing may be required.

The present method provides an improved ability to determine the performance of the instrument, because the measured QC sample spectrum more closely resembles the known, standard spectrum. The result is that the measured errors more directly relate to the instrument errors. Concomitantly, the difficult task of formulating stable QC products that mimic blood spectra is eliminated. Furthermore, one can use the same QC product on instruments using different wavelengths for measurement parameters and retain the ability to report the results at the same nominal value. These nominal values can be advantageously set to any desired value.



The present method further provides the ability to scale the concentration of blood components to better reflect anticipated instrument variations when physiological blood samples are run.

The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, to limit the invention in any way.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 displays three QC spectra of the three lots of CERTAIN® ELITE Level 1 QC product of Example 1.

FIG. 2 displays the spectra of the major absorbing blood components.

FIG. 3 displays the spectra that are the difference between the QC spectra of FIG. 1 and the least squares best fit to those spectra using the blood component spectra of FIG. 2.

FIG. 4 displays the error spectra, *i.e.*, the difference between the measured QC spectra of FIG. 1 and the least squares best fit standard QC, which in this case is the average of the three QC spectra of FIG. 1.

FIG. 5 displays the spectra that are the difference between the error spectrum of FIG. 4 and the least squares best fit to those spectra using the blood component spectra of FIG. 2.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides a new method for determining the performance level of an absorbance spectrophotometer. As used herein, the terms "absorbance spectrometer," "spectrometer," and their equivalents mean any machine or instrument capable of measuring the absorbance spectrum of a liquid sample. The present methods are particularly useful for determining the performance of CO-oximeters.

The methods comprise measuring the absorbance spectrum of a quality control (QC) sample and evaluating the quality of the fit to the known, standard spectrum for that QC product. The difference between the two is a measure of the performance of the spectrophotometer.

5 This method is distinguishable from prior art methods, which compare measured QC spectra to a standard blood spectrum. Because the QC spectra do not mimic blood spectra well, the observed differences in the measured QC spectrum and a standard blood spectrum are rather large (FIG. 3) and arise due to both variations on instrument performance as well as the inherent differences in the two spectra. The  
10 present methods improve upon this by greatly reducing or eliminating the inherent difference between the measured QC sample spectrum and the standard spectrum to which it is compared. FIGS. 3 and 4.

A shortcoming of the prior art is that blood component concentrations obtained from QC spectra often bear little or no relation to real values in blood, often  
15 appearing as negative concentrations or concentrations of greater than 100%. The present methods improve upon the prior art in that the instrumental error can be reported in terms of blood component concentrations that are comparable to real values in blood, and thus easily understandable to the technician in the field.

The inventive method is based on the well known Beer-Lambert law:

20 
$$A_{\lambda} = q_{\lambda} \cdot c \cdot x \quad (1)$$

where A is the absorbance at wavelength  $\lambda$ ,  $q_{\lambda}$  is the extinction coefficient at wavelength  $\lambda$  for the absorbent, c is the concentration of the absorbent, and x is the sample path length through which the measuring beam of light passes. The path length x is constant within the spectrophotometer (typically expressed in cm) and  
25 hereinafter will be subsumed in  $q_{\lambda}$ .

If there are "n" components in the sample, the Beer-Lambert law can be expressed in linear algebraic terms as:

$$A = q \cdot c, \quad (2)$$

where  $A$  is a vector whose "m" elements  $A_{\lambda_i}$  are the absorbencies at "m" discrete wavelengths  $\lambda_i$ ,  $q$  is an "m x n" matrix whose elements  $q_{ij}$  are the extinction coefficients of component "j" at wavelength  $\lambda_i$ , and  $c$  is a vector, each of whose "n" elements  $c_j$  is the concentration of component "j".

5 In the present invention, the absorbance spectrum ( $A_{\text{meas}}$ ) of a QC sample is measured (FIG. 1). The QC sample has a known set of extinction coefficients  $q$  as determined by measuring the absorbance spectrum or standard spectrum (with concentration  $c_{\text{std}}$ ) on a calibrated spectrophotometer. In practice, a standard absorbance spectrum ( $A_{\text{std}}$ ) of a QC product will be recorded on a high precision  
10 spectrophotometer and the concentration ( $c_{\text{std}}$ ) arbitrarily set to unity so that  $q = A_{\text{std}}$ . Alternatively, the standard QC spectrum may be obtained by averaging two or more QC sample spectra. The QC samples used to determine instrument performance are manufactured to be identical (i.e., have the same  $c_{\text{std}}$ ) to the QC product used to obtain  $A_{\text{std}}$ . It is noted that variation in the product specifications of different lots of QC  
15 products may impact the analysis, although this variation should be minor. The vector  $q$  is then electronically stored in the instrument by the manufacturer for use in future determinations of instrument performance.

The QC spectra will generally differ from the samples (e.g., blood samples) that are commonly analyzed on the spectrophotometer. As used herein, the term  
20 "analyze" means to determine the identity and/or concentration of component(s) of a sample. To give the most accurate and meaningful indication of instrument performance, the QC sample should preferably be constructed to give an absorbance spectrum closely mimicking that of samples frequently analyzed on the spectrophotometer. In a preferred embodiment, the QC sample will mimic human  
25 blood. QC products suitable for use in the invention are commercially available, for example, from Ciba Corning Diagnostics Corp. (Medfield, MA) under the trade name CERTAIN® ELITE.

The standard QC spectrum,  $A_{std}$ , is fit to the measured spectrum,  $A_{mes}$ , by treating "c" in equation (2) as a variable and determining the value of "c" that results in the best fit. The result is an apparent concentration of the QC,  $c_{app}$ . A variety of potential sources of instrumental error will result in  $A_{mes}$  differing from  $A_{std}$  and, consequently,  $c_{app}$  differing from  $c_{std}$ . Any of the well known mathematical techniques of fitting spectra can be used to determine the best fit of  $A_{std}$  to  $A_{mes}$  and from it  $c_{app}$ . See Press et al., *Numerical Recipes: The Art of Scientific Computing* Ch. 14, pp. 498-546 (Cambridge University Press, Cambridge, 1986). In a preferred embodiment,  $c_{app}$  is obtained by a least squares analysis and is given by:

$$c_{app} = (q^T q)^{-1} q^T \cdot A_{mes} \quad (3)$$

See Noble and Daniel, *Applied Linear Algebra*, pp. 57-65 (Prentice-Hall 1977). The apparent concentration,  $c_{app}$ , can then be used to give the estimated, best fit (in the least squares sense) absorbance spectrum,  $A_{est}$ :

$$A_{est} = q \cdot c_{app} \quad (4)$$

The difference between the measured and estimated absorbance spectra at each wavelength, i.e., the "error spectrum" is given by the vector E:

$$E = A_{est} - A_{mes} \quad (5)$$

(FIG. 4). The vector E is a measure of the deviation of instrumental performance from the ideal.

It is difficult to determine from E itself, however, the level of instrument performance and whether the instrument is performing within acceptable standards. In a preferred embodiment of the present invention, E is advantageously related to errors in the measured concentration of blood components ( $C_{\Delta FB}$ ) that would result from the instrumental errors.  $C_{\Delta FB}$  is a vector having "k" elements, each being the error in concentration of one of the blood components.  $C_{\Delta FB}$  is the vector of blood component concentrations that would give rise to the observed error spectrum, E.  $C_{\Delta FB}$  can be determined in a variety of ways involving fitting the error spectrum with one or more known blood component spectra by varying the intensities of each blood

component spectrum. The relative contributions of each of the blood component spectrum are the relative concentrations of each of the components. Preferably, the least squares method is used. If  $Q_{Hb}$  is the "k x m" matrix of extinction coefficients for "k" blood components at "m" wavelengths, then  $C_{\Delta Hb}$  is given by:

$$5 \quad C_{\Delta Hb} = (Q_{Hb}^T Q_{Hb})^{-1} Q_{Hb}^T \cdot E. \quad (6a)$$

or

$$C_{\Delta Hb} = W \cdot (Q_{Hb}^T Q_{Hb})^{-1} Q_{Hb}^T \cdot E. \quad (6b)$$

The  $C_{\Delta Hb}$  thus obtained will have the same units as  $Q_{Hb}$ , preferably gm/dL. The values of  $C_{\Delta Hb}$  can be positive (indicating that the instrumental errors would result in measured blood component concentrations that are too high) or negative (indicating that instrumental error would result in measured blood component concentrations that are too low). If all elements of E were zero, i.e.,  $A_{meas} = A_{std}$ , meaning the instrument was performing ideally, there would be no error in the measurements of the concentrations of blood components, and all elements of  $C_{\Delta Hb}$  would be zero.

15      Weight or W is a matrix which scales the concentration of blood components to better reflect anticipated instrument variations when physiological blood samples are run. The simplest case is when the diagonal elements equal 1 and the others are 0.

Equation 6b provides a transformation of the error concentrations obtained with QC so that they reflect values that would have been obtained if the sample was oxyhemoglobin. A physiological sample transformation is a matrix which weights each fraction of error to adjust it to a new value. Errors due to instrument inaccuracies, such as spectral or wavelength shift, result in characteristic errors for each hemoglobin fraction as well as each quality control. The characteristic response of the instrument to such inaccuracies can be predetermined for any specific sample.

20      Since physiological samples are predominantly oxyhemoglobin and since the characteristic response of the instrument (due to inaccuracies) will be different for samples other than oxyhemoglobin, it is desirable to compensate for these differences.

In another preferred embodiment of the invention, the total concentration of hemoglobin is reported ( $T_{app}$ ). It is the product of the apparent concentration of the QC measured,  $c_{app}$ , and the nominal value of total hemoglobin,  $T_{nom}$ :

$$T_{app} = T_{nom} \cdot c_{app} \quad (7)$$

- 5  $T_{nom}$  can be set to any convenient value. In a preferred embodiment,  $T_{nom} = 14$  g/dL, a value typical of normal human blood. Thus, if  $c_{app} = 1$  (which is the arbitrary value chosen for the QC product and would result if  $A_{meas} = A_{std}$ ), the reported total hemoglobin would be the same as that observed in normal human blood.

The nominal concentration of the "k" blood components,  $C_{nom}$ , is given by:

$$10 \quad C_{nom} = F_{nom} \cdot T_{nom} \quad (8)$$

where  $F_{nom}$  is the vector each of whose elements  $F_{nom,i}$  are the nominal fractions of blood component "i." In a preferred embodiment of the present invention, the elements of  $F_{nom}$  are set to the actual fractions of the blood components observed in human blood.

- 15 The apparent concentration of blood components that one would observe on the instrument being tested ( $C_{Hb,app}$ ) is the sum of the nominal concentrations ( $C_{nom}$ ) and the errors in blood component concentrations previously calculated,  $C_{\Delta Hb}$ :

$$C_{Hb,app} = C_{nom} + C_{\Delta Hb} \quad (9)$$

- 20 The total calculated hemoglobin concentration (the scalar  $T_{calc}$ ) is the sum of the calculated values of the components, i.e., the sum of the elements of the vector  $C_{Hb,app}$ . The reported fractions of the blood components  $F_{rep}$  is then given by:

$$F_{rep} = C_{Hb,app} / T_{calc} \quad (10)$$

- 25 Evaluation of any one or more of the foregoing indicia of instrumental performance will allow the field technician to determine whether servicing of the spectrophotometer is required or that test sample analysis may proceed.

That is, one may observe any one or more of the following:

1. the deviation of the best fit quality control spectrum ( $A_{est}$ ) from the measured QC spectrum ( $A_{meas}$ ) or, equivalently, the error spectrum, E;

2. the deviation of  $c_{app}$  from  $c_{std}$ ;
3.  $C_{\Delta Hb}$ ;
4. the deviation of  $T_{app}$  or  $T_{calc}$  from  $T_{nom}$ ;
5. the deviation of  $C_{Hb,app}$  from  $C_{nom}$ ;
- 5 6. the deviation of  $F_{rep}$  from  $F_{nom}$ ; and
7. any equivalent indicium of instrumental performance derived from the comparison of  $A_{meas}$  and  $A_{std}$ .

Acceptable limits within which the instrument is required to perform will depend on the particular circumstances and will vary from application to application. For instance, in cases where only rough estimates of concentrations are needed, a larger deviation of any of the foregoing parameters from the ideal can be tolerated. On the other hand, where extremely precise measurements of concentration are required, only small deviations in the foregoing parameters will be acceptable. Typical acceptable values will vary within about  $\pm 2\%$  of the nominal value.

15 The major components of blood that will ordinarily be used in the present methods are reduced hemoglobin (HHb), oxygenated hemoglobin ( $O_2Hb$ ), carboxy hemoglobin (COHb), met hemoglobin (MetHb), sulf hemoglobin (SHb), and lipid. The extinction coefficients for hemoglobin-based blood components can be measured directly or obtained from the literature. See Zijlstra et al., *Clin. Chem.* 37(9), 1633-20 1638 (1991). The lipid spectrum can be measured from intravenous fat emulsion (e.g., the commercially available lipid product LIPOSYN™ II) in an aqueous dispersion of about 10% by weight.

Any number of wavelengths can be used to measure and fit the foregoing spectra, but at a minimum there must be at least as many wavelengths as there are variables (i.e., concentrations) to be fit. The larger the number of wavelengths used, the less contribution there will be from random noise and, therefore, the more accurate the measurements. As a practical matter, seven wavelengths can be used to fit an error spectrum with 6 component spectra, e.g., HHb,  $O_2Hb$ , COHb, MetHb, SHb, and lipid.

Preferably the spectra are measured and fit at wavelengths at which the QC products have at least a moderate level of absorbance.

The following examples are offered for illustrative purposes only and are not intended, nor should they be construed, to limit the invention in any manner.

5

## EXAMPLES

### Example 1

The methods of the present invention were applied to three different lots of three different CERTAIN® ELITE (Ciba Corning Diagnostics, Medfield, MA) QC products, Levels 1, 2, and 3. In this Example, the standard QC spectrum was obtained by averaging the QC sample spectra of the three lots 1-3 at each level. Accordingly, the deviations observed in this Example arise from differences in the QC sample lots.

The deviations from the standard spectrum, however, are representative of deviations one would observe from instrumental errors.

15 Absorbance spectra were obtained on a CARY IV (Varian Instruments, Palo Alto, CA) and are displayed in FIG. 1 for QC Level 1 lots 1-3. The error spectra were fit at seven wavelengths in the range of 550-650 nm using absorbance spectra of HHb, MetHb, O<sub>2</sub>Hb, COHb, SHb, and lipid. The reported results for the present method were calculated using the methods described above. The results are displayed below.

20 As can be seen, the values for the concentrations of blood components calculated using the present method correspond to values one might observe for real blood. By contrast, the values of blood component concentrations using prior art methods can be negative or greater than 100% of the total hemoglobin.



**QC LEVEL 1** -  $T_{nom} = 11.5$  gm/dL

**Mean QC Concentration**

	Lot 1	Lot 2	Lot 3
<b>Concentration (<math>C_{app}</math>)</b>	0.995	1.009	0.996
<b>Concentration error</b>	-0.005	0.009	-0.004

5

**Blood Component Concentration Errors**

	$C_{\Delta Hb,i}$ (gm/dL)			$(C_{\Delta Hb,i} / T_{nom}) \times 100\% = \%$ Error		
	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
<b>HHb</b>	0.055	0.005	-0.060	0.48	0.04	-0.52
<b>O<sub>2</sub>Hb</b>	-0.016	0.012	0.003	-0.14	0.10	0.03
<b>CO<sub>2</sub>Hb</b>	0.040	-0.031	-0.009	0.35	-0.27	-0.08
<b>MetHb</b>	0.053	-0.017	-0.037	0.46	-0.15	-0.32

Reported Results ( $F_{nom,j} \times 100\%$ )

	Nominal Value	Present Method			Prior Art Method		
		Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
HHb	3	3.44	3.05	2.50	2.7	2.3	1.7
O <sub>2</sub> Hb	93	91.80	93.36	93.87	-22.1	-22.2	-22.4
CO <sub>2</sub> Hb	2	2.32	1.73	1.94	121.3	122.6	123.4
MetHb	2	2.43	1.86	1.70	-1.8	-2.6	-2.7
$T_{app,j} = c_{app} \cdot T_{nom,j}$		11.44	11.60	11.45	11.71	11.69	11.48

5 QC LEVEL 2 -  $T_{nom} = 17.5$  gm/dL

## Mean QC Concentration

	Lot 1	Lot 2	Lot 3
Concentration ( $C_{app}$ )	1.006	1.003	0.991
Concentration error	0.006	0.003	-0.009

## Blood Component Concentration Errors

	$C_{\Delta Hb,i}$ (gm/dL)			$(C_{\Delta Hb,i} / T_{nom}) \times 100\% = \%$ Error		
	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
HHb	0.03	0.04	-0.068	0.17	0.23	-0.39
O <sub>2</sub> Hb	0.012	0.002	-0.012	0.07	0.01	-0.07
CO <sub>2</sub> Hb	-0.053	0.009	0.044	-0.03	0.05	0.25
MetHb	0.011	0.012	-0.021	0.06	0.07	-0.12

5

Reported Results ( $F_{nom,i} \times 100\%$ )

	Nominal Value	Present Method			Prior Art Method		
		Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
HHb	3	3.00	2.99	3.01	11.7	11.7	11.1
O <sub>2</sub> Hb	93	93.23	92.96	92.8	-18.5	-18.5	-18.7
CO <sub>2</sub> Hb	2	2.07	2.00	1.93	110.1	110	110.8
MetHb	2	1.7	2.04	2.25	-3.2	-3.2	-3.3
$T_{app,i} = C_{app} \cdot T_{nom,i}$		17.61	17.55	17.34	17.82	17.51	17.72

**QC LEVEL 3 -  $T_{nom} = 20.8$  gm/dL**

**Mean QC Concentration**

	Lot 1	Lot 2	Lot 3
<b>Concentration (<math>C_{app}</math>)</b>	1.011	0.987	1.002
<b>Concentration error</b>	0.011	-0.013	0.002

5

**Blood Component Concentration Errors**

	$C_{\Delta Hb,i}$ (gm/dL)			$(C_{\Delta Hb,i} / T_{nom}) \times 100\% = \%$ Error		
	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
<b>HHb</b>	0.006	-0.017	0.01	0.03	-0.08	0.05
<b>O<sub>2</sub>Hb</b>	-0.017	-0.01	0.027	-0.08	-0.05	0.13
<b>CO<sub>2</sub>Hb</b>	-0.01	0.071	-0.06	-0.05	0.34	-0.29
<b>MetHb</b>	-0.002	0.006	-0.004	-0.01	0.03	-0.02

Reported Results ( $F_{nom,j} \times 100\%$ )

	Nominal Value	Present Method			Prior Art Method		
		Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
HHb	3	3.00	3.00	2.99	16.1	15.9	16.1
O <sub>2</sub> Hb	93	93.05	93.12	92.83	-16.7	-16.6	-16.5
CO <sub>2</sub> Hb	2	2.03	1.92	2.05	104.1	104.2	103.9
MetHb	2	1.92	1.95	2.13	-3.5	-3.4	-3.5
$T_{app,j} = c_{app} \cdot T_{nom,j}$		21.03	20.53	20.84	20.81	21.05	21.03

5

## Example 2

The QC Level 1, lots 1-3 spectra displayed in FIG. 1 were fit using a least squares analysis by the blood component spectra of FIG. 2. The difference between the best fit and the QC spectra are displayed in FIG. 3. As can be seen, the differences are orders of magnitude larger than the error spectrum obtained by subtracting the best fit QC spectra from the measured QC spectra.

10

I claim:


1. A method of determining the quality of performance of an absorbance spectrometer, the method comprising:
  - a. measuring the absorbance spectrum of a quality control sample;
  - 5      b. fitting the measured sample spectrum with the standard spectrum of the quality control product sample to obtain a best fit spectrum and an apparent concentration of the quality control sample; and
  - c. evaluating the quality of the fit.
- 10      2. The method, according to claim 1, wherein the quality of the fit is evaluated by calculating the difference between the best fit spectrum and the measured spectrum to yield an error spectrum.
- 15      3. The method, according to claim 1, wherein the quality of the fit is evaluated by determining the deviation of the apparent concentration of the quality control sample,  $c_{app}$ , from the concentration of the standard quality control sample,  $c_{std}$ .
- 20      4. The method, according to claim 2, wherein a least squares analysis is used to fit the standard spectrum to the measured spectrum.
- 25      5. The method, according to claim 3, wherein a least squares analysis is used to fit the standard spectrum to the measured spectrum.
6. The method, according to claim 1, wherein the quality of the fit is evaluated by fitting one or more blood component spectra to the error spectrum to yield errors in concentrations of blood components.

7. The method, according to claim 6, wherein a least squares analysis is used to fit the standard spectrum for the quality control to the measured spectrum and to fit the one or more blood component spectra to the error spectrum.
- 5 8. The method, according to claim 1, wherein the quality of the fit is evaluated by selecting a nominal total concentration of hemoglobin, multiplying the nominal total concentration of hemoglobin by the apparent quality control sample concentration to yield an apparent total hemoglobin concentration.
- 10 9. The method, according to claim 8, wherein a least squares analysis is used to fit the standard spectrum for the quality control sample to the measured spectrum.
- 15 10. The method, according to claim 6, wherein the quality of the fit is evaluated by selecting nominal values of concentrations of the blood components, adding the errors in concentrations of blood components to their respective nominal concentration values to yield apparent concentrations of the blood components, and evaluating the apparent concentrations of blood components.
- 20 11. The method, according to claim 10, wherein a least squares analysis is used to fit the standard spectrum for the quality control sample to the measured spectrum and to fit the one or more blood component spectra to the error spectrum.
- 25 12. The method, according to claim 10, wherein the quality of the fit is determined by selecting a nominal total concentration of hemoglobin, multiplying the nominal total concentration of hemoglobin by the apparent quality control sample concentration to yield an apparent total hemoglobin concentration, and dividing the nominal concentrations of hemoglobin components by the apparent total hemoglobin concentration to obtain fractional concentrations of hemoglobin components.

13. The method, according to claim 6, wherein the concentration of blood components are weighted to reflect anticipated instrument variations.
- 5 14. The method, according to claim 1, wherein said standard quality control product has similar connotations of one or more absorbing components of the quality control sample.
- 10 15. The method, according to claim 1, further comprising the step of measuring the absorbance spectrum of a test sample.
- 15 16. A method for performing absorbance spectrophotometer analysis comprising:
- a. measuring the absorbance spectrum of a quality control product;
  - b. fitting the measured spectrum with a standard spectrum of a quality control product having the similar concentration of one or more absorbing components to obtain a best fit spectrum and an apparent concentration of the quality control sample;
  - c. evaluating the quality of the fit; and
  - d. measuring the absorbance spectrum of a test sample.
- 20 17. A method for calibrating an absorbance spectrophotometer comprising:
- a. measuring the absorbance spectrum for a plurality of quality control samples, wherein said quality control samples correspond to a blood component spectra;
  - 25 b. fitting the measured spectrum with a standard spectrum of a quality control product having the same concentration of absorbing components to obtain a best fit spectrum and an apparent concentration of the quality control sample;



- c. evaluating the quality of the fit; and
- d. adjusting the calibration of said spectrophotometer.



$(\text{level}_1^{<0>})_{wi}$   
 $(\text{level}_1^{<1>})_{wi}$   
 $(\text{level}_1^{<2>})_{wi}$

FIG. 1





FIG. 2


3/5



Wavelength (nm)

 $\left( \text{level\_1\_blood\_err} \right)_{\text{nwave}}^{<0>}$  $\left( \text{level\_1\_blood\_err} \right)_{\text{nwave}}^{<1>}$  $\left( \text{level\_1\_blood\_err} \right)_{\text{nwave}}^{<2>}$ 

FIG. 3



$$\begin{aligned} & \left( \text{level}_1 \right)_{qc\_err} \langle 0 \rangle_{wi} \\ & \left( \text{level}_1 \right)_{qc\_err} \langle 1 \rangle_{wi} \\ & \left( \text{level}_1 \right)_{qc\_err} \langle 2 \rangle_{wi} \end{aligned}$$

FIG. 4

5/5




FIG. 5

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IB 96/00260

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N21/27

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 03341 (DOW CHEMICAL COMPANY) 18 February 1993  see abstract see page 3, line 5 - line 19 see page 3, line 26 - line 33 see page 4, line 6 - line 13 see page 5, line 3 - line 17 see page 5, line 27 - line 31	1-5, 10-12, 15-17
Y	see figures 1,3A,4A,4B	6
Y	--- WO,A,92 22804 (FUTREX) 23 December 1992 see page 7, line 3 - page 8, line 5 see page 8, line 11 - page 9, line 4 see figure 2  --- -/-	6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

6 June 1996

Date of mailing of the international search report

19. 06. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2230 HV Rijswijk  
T'd. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thomas, R.M.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 96/00260

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF CHEMOMETRICS, vol. 2, 1988, pages 93-109, XP002004968 A. LORBER ET AL.: "Estimation of prediction error for multivariate calibration" see page 107, last paragraph - page 108, line 3 see page 94, paragraph 2 ---	6
A	CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, vol. 25, no. 2, November 1994, AMSTERDAM NL, pages 85-97, XP002004969 O.E. DE NOORD: "Multivariate calibration standardization" see page 96, left-hand column, line 4 - right-hand column, line 6 ---	
A	ANALYTICAL CHEMISTRY, vol. 63, no. 23, 1 December 1991, COLUMBUS US, pages 2750-2756, XP000249569 WANG ET AL.: "Multivariate instrument calibration" ---	
A	US,A,5 243 546 (MAGGARD) 7 September 1993 -----	



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/IB 96/00260

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9303341	18-02-93	US-A- 5357336	18-10-94
		CA-A- 2111963	18-02-93
		EP-A- 0598015	25-05-94
		JP-T- 6509871	02-11-94
-----	-----	-----	-----
WO-A-9222804	23-12-92	US-A- 5204532	20-04-93
		AU-B- 2251292	12-01-93
		CA-A- 2111868	23-12-92
		EP-A- 0590077	06-04-94
		JP-T- 6508440	22-09-94
-----	-----	-----	-----
US-A-5243546	07-09-93	NONE	
-----	-----	-----	-----

**THIS PAGE BLANK (USPTO)**